DSID,AU,TI,JR,PY,VL,IS,PG,AB,SA,REGID,STD.IND,STD.DESIGN,STD.GEO.LOCATION,STD.PHASE,ARM.NUM,ARM.BLIND,ARM.RANDFLG,ARM.TRT,ARM.TRTCLASS,ARM.DOSE,ARM.DOSEU,ARM.ROUTE,ARM.REGIMEN,ARM.FORMULATION,N.STUDY,N.ARM,N.ARM.STATANAL,N.ARM.EVENT.SUBJ,STATANAL.POP,STATANAL.METHOD,STATANAL.IMP.METHOD,ARM.TIME1,ARM.TIME1U,ENDPOINT,BSL.STAT,BSL.VAL,BSL.VALU,BSL.VAR,BSL.VARU,BSL.LCI,BSL.UCI,CHBSL.STAT,CHBSL.VAL,CHBSL.VALU,CHBSL.VAR,CHBSL.VARU,CHBSL.LCI,CHBSL.UCI,RSP.STAT,RSP.VAL,RSP.VALU,RSP.VAR,RSP.VARU,RSP.LCI,RSP.UCI,PCHBSL.STAT,PCHBSL.VAL,PCHBSL.VAR,PCHBSL.VARU,PCHBSL.LCI,PCHBSL.UCI,ARM.PCT.MALE,ARM.AGE,ARM.AGEU
1027,Kashiwagi A; Kazuta K; Goto K; Yoshida S; Ueyama E; Utsuno A,"Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study",DIABETES.OBES.METAB,2015,17,,304~8,,ILLUMINATE,NCT01135433,T2D,Parallel,JP,Phase 3,0.0,Double-Blind,True,placebo,Placebo,0,MG/DAY,,QD,,169,56.0,56,,FAS,,LOCF,24.0,WK,HbA1c,Mean,8.38,percent,0.738,SD,,,Mean,0.38,percent,0.703,SD,0.192,0.568,Mean,8.76,percent,0.912,SD,8.516,9.004,Mean,4.535,,,,,58.9,57.7,YR
1027,Kashiwagi A; Kazuta K; Goto K; Yoshida S; Ueyama E; Utsuno A,"Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study",DIABETES.OBES.METAB,2015,17,,304~8,,ILLUMINATE,NCT01135433,T2D,Parallel,JP,Phase 3,1.0,Double-Blind,True,ipragliflozin,SGLT2,50,MG/DAY,,QD,,169,112.0,112,,FAS,,LOCF,24.0,WK,HbA1c,Mean,8.25,percent,0.719,SD,,,Mean,-0.87,percent,0.655,SD,-0.993,-0.747,Mean,7.38,percent,0.712,SD,7.247,7.513,Mean,-10.545,,,,,58.9,56.2,YR
